Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
Sharma S, Abhyankar V, Burgess RE, Infante J, Trowbridge RC, Tarazi J, Kim S, Tortorici M, Chen Y, Robles RL. Sharma S, et al. Among authors: tortorici m. Ann Oncol. 2010 Feb;21(2):297-304. doi: 10.1093/annonc/mdp489. Epub 2009 Nov 25. Ann Oncol. 2010. PMID: 19940012 Free article. Clinical Trial.
Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours.
Kozloff MF, Martin LP, Krzakowski M, Samuel TA, Rado TA, Arriola E, De Castro Carpeño J, Herbst RS, Tarazi J, Kim S, Rosbrook B, Tortorici M, Olszanski AJ, Cohen RB. Kozloff MF, et al. Among authors: tortorici m. Br J Cancer. 2012 Oct 9;107(8):1277-85. doi: 10.1038/bjc.2012.406. Epub 2012 Sep 18. Br J Cancer. 2012. PMID: 22990652 Free PMC article. Clinical Trial.
Clinical pharmacology of axitinib.
Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK. Chen Y, et al. Among authors: tortorici ma. Clin Pharmacokinet. 2013 Sep;52(9):713-25. doi: 10.1007/s40262-013-0068-3. Clin Pharmacokinet. 2013. PMID: 23677771 Review.
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Cohen EE, et al. Among authors: tortorici m. J Clin Oncol. 2008 Oct 10;26(29):4708-13. doi: 10.1200/JCO.2007.15.9566. Epub 2008 Jun 9. J Clin Oncol. 2008. PMID: 18541897 Free PMC article. Clinical Trial.
Axitinib plasma pharmacokinetics and ethnic differences.
Chen Y, Suzuki A, Tortorici MA, Garrett M, LaBadie RR, Umeyama Y, Pithavala YK. Chen Y, et al. Among authors: tortorici ma. Invest New Drugs. 2015 Apr;33(2):521-32. doi: 10.1007/s10637-015-0214-x. Epub 2015 Feb 8. Invest New Drugs. 2015. PMID: 25663295 Review.
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. Cohen EE, et al. Among authors: tortorici m. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. doi: 10.1007/s00280-014-2604-8. Epub 2014 Oct 15. Cancer Chemother Pharmacol. 2014. PMID: 25315258 Free PMC article. Clinical Trial.
168 results